Open Access

Predictive value of using plasma long non‑coding RNAs ANRIL and HOXA11‑AS for in‑stent restenosis

  • Authors:
    • Zhijiang Jin
    • Hongfeng Shen
    • Wei Cha
    • Haijiang Xia
    • Longbin Liu
  • View Affiliations

  • Published online on: December 6, 2021     https://doi.org/10.3892/etm.2021.11038
  • Article Number: 115
  • Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In‑stent restenosis (ISR) can pose serious challenges for cardiologists following coronary stent implantation. Early identification of patients at high risk of ISR is considered to be effective for its prevention. However, factors that can reliably predict the risk of ISR remain elusive at present. The present study aimed to investigate the possible association between plasma long non‑coding RNA (lncRNA) levels and ISR. A total of 410 patients with single‑vessel lesion who received drug‑eluting stents (DES) were included in the present study. After 12‑36 months of follow‑up, coronary angiography was performed and ISR was defined as >50% diameter stenosis at follow‑up. RT‑qPCR was used to measure lncRNA expression. Expression of the lncRNA RNA antisense non‑coding RNA at the INK4 locus (ANRIL) was found to be upregulated whereas the lncRNA homeobox A11 antisense (HOXA11‑AS) was downregulated in the plasma of patients with ISR compared with that from patients without ISR (P<0.001). Logistic regression analysis revealed that ANRIL [odds ratio (OR)=2.95; 95% confidence interval (CI)=1.68‑8.08] was an independent risk factor for ISR, whilst HOXA11‑AS (OR=0.58; 95% CI=0.48‑0.71) was found to be an independent protective factor for ISR. Receiver operating characteristic (ROC) analysis demonstrated that high ANRIL expression [area under the ROC (auROC)=0.755; 95% CI=0.702‑0.803] and low HOXA11‑AS levels (auROC=0.712; 95% CI=0.657‑0.763) predicted a high risk for ISR, and the combined score of ANRIL and HOXA11‑AS (auROC=0.844; 95% CI=0.798‑0.884) was more efficient at predicting ISR than either ANRIL or HOXA11‑AS alone (P<0.001). In conclusion, increased ANRIL and decreased HOXA11‑AS expressions were associated with ISR. However, combined ANRIL and HOXA11‑AS plasma levels proved to be more effective at predicting ISR compared with either ANRIL or HOXA11‑AS alone, suggesting that the multiplex detection of lncRNAs could be used to predict ISR in the future.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 23 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jin Z, Shen H, Cha W, Xia H and Liu L: Predictive value of using plasma long non‑coding RNAs ANRIL and HOXA11‑AS for in‑stent restenosis. Exp Ther Med 23: 115, 2022
APA
Jin, Z., Shen, H., Cha, W., Xia, H., & Liu, L. (2022). Predictive value of using plasma long non‑coding RNAs ANRIL and HOXA11‑AS for in‑stent restenosis. Experimental and Therapeutic Medicine, 23, 115. https://doi.org/10.3892/etm.2021.11038
MLA
Jin, Z., Shen, H., Cha, W., Xia, H., Liu, L."Predictive value of using plasma long non‑coding RNAs ANRIL and HOXA11‑AS for in‑stent restenosis". Experimental and Therapeutic Medicine 23.2 (2022): 115.
Chicago
Jin, Z., Shen, H., Cha, W., Xia, H., Liu, L."Predictive value of using plasma long non‑coding RNAs ANRIL and HOXA11‑AS for in‑stent restenosis". Experimental and Therapeutic Medicine 23, no. 2 (2022): 115. https://doi.org/10.3892/etm.2021.11038